Acumen Pharmaceuticals Announces First Patient Dosed in Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease
Acumen Pharmicals宣佈首次給患者服用Altitude-Ad劑量,這是一項針對早期阿爾茨海默氏病的Sabirnetug(Acu193)的2期臨床試驗
Acumen Pharmaceuticals Announces First Patient Dosed in Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease
Acumen Pharmicals宣佈首次給患者服用Altitude-Ad劑量,這是一項針對早期阿爾茨海默氏病的Sabirnetug(Acu193)的2期臨床試驗
使用瀏覽器的分享功能,分享給你的好友吧